Systemic Sclerosis (Scleroderma) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Systemic Sclerosis (Scleroderma) – Pipeline Review, H2 2017’, provides an overview of the Systemic Sclerosis (Scleroderma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)

The report reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Systemic Sclerosis (Scleroderma) therapeutics and enlists all their major and minor projects

The report assesses Systemic Sclerosis (Scleroderma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

AnaMar AB

Angion Biomedica Corp

arGentis Pharmaceuticals LLC

Bayer AG

Biogen Inc

BLR Bio LLC

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Covis Pharmaceuticals Inc

CSL Ltd

Cumberland Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Fibrocell Science Inc

GenKyoTex SA

Gilead Sciences Inc

GlaxoSmithKline Plc

iBio Inc

Inventiva

Leadiant Biosciences Inc

MedImmune LLC

Patagonia Pharmaceuticals LLC

PDX Pharmaceuticals LLC

Peptinov SAS

ProMetic Life Sciences Inc

Ribomic Inc

Samumed LLC

Sanofi

Seattle Genetics Inc

Stemline Therapeutics Inc

Stratatech Corp

Vicore Pharma AB

viDA Therapeutics Inc

VivaCell Biotechnology Espana SL

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Systemic Sclerosis (Scleroderma) - Overview 8

Systemic Sclerosis (Scleroderma) - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Systemic Sclerosis (Scleroderma) - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 23

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development 31

Allergan Plc 31

AnaMar AB 31

Angion Biomedica Corp 32

arGentis Pharmaceuticals LLC 32

Bayer AG 33

Biogen Inc 33

BLR Bio LLC 34

Boehringer Ingelheim GmbH 34

Bristol-Myers Squibb Company 35

Covis Pharmaceuticals Inc 35

CSL Ltd 36

Cumberland Pharmaceuticals Inc 36

F. Hoffmann-La Roche Ltd 37

Fibrocell Science Inc 37

GenKyoTex SA 38

Gilead Sciences Inc 38

GlaxoSmithKline Plc 39

iBio Inc 39

Inventiva 40

Leadiant Biosciences Inc 40

MedImmune LLC 41

Patagonia Pharmaceuticals LLC 41

PDX Pharmaceuticals LLC 42

Peptinov SAS 42

ProMetic Life Sciences Inc 43

Ribomic Inc 43

Samumed LLC 44

Sanofi 44

Seattle Genetics Inc 45

Stemline Therapeutics Inc 45

Stratatech Corp 46

Vicore Pharma AB 46

viDA Therapeutics Inc 47

VivaCell Biotechnology Espana SL 47

Systemic Sclerosis (Scleroderma) - Drug Profiles 48

abatacept - Drug Profile 48

acALY-18 - Drug Profile 56

ambrisentan - Drug Profile 57

anabasum - Drug Profile 60

ANG-3070 - Drug Profile 68

ARG-201 - Drug Profile 69

belimumab - Drug Profile 71

BLR-200 - Drug Profile 78

brentuximab vedotin - Drug Profile 79

C-1889 - Drug Profile 106

C-21 - Drug Profile 108

C-82 - Drug Profile 111

Cell Therapy for Dermatology and Immunology - Drug Profile 112

CM-101 - Drug Profile 114

dimethyl fumarate DR - Drug Profile 115

elapegademase - Drug Profile 120

factor XIII (human) - Drug Profile 121

FCX-013 - Drug Profile 122

GKT-831 - Drug Profile 123

GSK-2330811 - Drug Profile 127

IBIOCFB-03 - Drug Profile 128

ifetroban sodium - Drug Profile 130

IVA-337 - Drug Profile 132

M-10 - Drug Profile 134

MEDI-7734 - Drug Profile 135

miRNA-29 - Drug Profile 136

Monoclonal Antibodies to Antagonize IL-3RA for Autoimmune Disorders - Drug Profile 137

nintedanib - Drug Profile 138

nitroglycerin - Drug Profile 149

onabotulinumtoxinA - Drug Profile 151

PAT-048 - Drug Profile 156

PATS-03 - Drug Profile 157

PBI-4050 - Drug Profile 158

PBI-4425 - Drug Profile 166

PDX-002 - Drug Profile 167

PPV-06 - Drug Profile 168

RBM-006 - Drug Profile 169

riociguat - Drug Profile 170

rituximab biosimilar - Drug Profile 176

RP-182 - Drug Profile 177

SAR-100842 - Drug Profile 178

SAR-156597 - Drug Profile 179

SAR-317461 - Drug Profile 180

SM-04755 - Drug Profile 181

Small Molecule to Inhibit NFkB for Autoimmune Disorders, Melanoma and Inflammation - Drug Profile 183

Small Molecules to Antagonize 5-HT2B for Idiopathic Pulmonary Fibrosis and Systemic Sclerosis - Drug Profile 184

sodium nitrite SR - Drug Profile 185

Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile 187

terguride - Drug Profile 188

tocilizumab - Drug Profile 189

TRX-101 - Drug Profile 199

VCE-0048 - Drug Profile 200

VEDA-1209 - Drug Profile 201

VTI-1000 Series - Drug Profile 202

Wnt-001 - Drug Profile 203

Systemic Sclerosis (Scleroderma) - Dormant Projects 204

Systemic Sclerosis (Scleroderma) - Discontinued Products 206

Systemic Sclerosis (Scleroderma) - Product Development Milestones 207

Featured News & Press Releases 207

Appendix 220

Methodology 220

Coverage 220

Secondary Research 220

Primary Research 220

Expert Panel Validation 220

Contact Us 220

Disclaimer 221

List of Tables

List of Tables

Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Allergan Plc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by AnaMar AB, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Angion Biomedica Corp, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by arGentis Pharmaceuticals LLC, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Bayer AG, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Biogen Inc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by BLR Bio LLC, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Boehringer Ingelheim GmbH, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Bristol-Myers Squibb Company, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Covis Pharmaceuticals Inc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by CSL Ltd, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Cumberland Pharmaceuticals Inc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Fibrocell Science Inc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by GenKyoTex SA, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Gilead Sciences Inc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by GlaxoSmithKline Plc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by iBio Inc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Inventiva, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Leadiant Biosciences Inc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by MedImmune LLC, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Patagonia Pharmaceuticals LLC, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by PDX Pharmaceuticals LLC, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Peptinov SAS, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by ProMetic Life Sciences Inc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Ribomic Inc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Samumed LLC, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Sanofi, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Seattle Genetics Inc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Stemline Therapeutics Inc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Stratatech Corp, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by Vicore Pharma AB, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by viDA Therapeutics Inc, H2 2017

Systemic Sclerosis (Scleroderma) – Pipeline by VivaCell Biotechnology Espana SL, H2 2017

Systemic Sclerosis (Scleroderma) – Dormant Projects, H2 2017

Systemic Sclerosis (Scleroderma) – Dormant Projects, H2 2017 (Contd..1), H2 2017

Systemic Sclerosis (Scleroderma) – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports